Clinical Research Directory

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Sponsor: University Health Network, Toronto

Summary

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

Key Details

Conditions

Locations (1)